Clinical trial · Observational
A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer
A Non Interventional Trial of Tarceva Metastatic Non Small Lung Cancer.
NCT02595450CI-TRIAL-00020633completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a non-interventional, open label, single arm, multicenter study to assess the safety and efficacy of erlotinib in participants with non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Erlotinib | Drug | Erlotinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Erlotinib
- description
- Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
- interventionNames
- Drug: Erlotinib
Primary outcomes (2)
- measure
- Progression-free Survival (PFS) Time
- timeFrame
- Up to 6 years
- description
- Time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. Progression was defined as at least 20 percent (%) increase in the sum of diameters of target lesions, or unequivocal progression of existing non-target lesions. Kaplan-Meier estimates were used for calculating PFS.
- measure
- Percentage of Participants With Best Overall Response
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
- Maximum age
- 86 Years
Show eligibility criteria text
Inclusion Criteria: * It is the physician's decision to prescribe erlotinib in participants and to document their treatment * Participants must be candidates for receiving erlotinib for locally advanced or metastatic non-small cell lung cancer according to the product label Exclusion Criteria: * Participants will be excluded if safety concerns occurred * If the participant was not compliant or if the participant would wish to stop erlotinib therapy
References
Publications (0)
Data not yet available
No reference posted for this study.